DiCE Molecules
Ms. Patel joined DiCE Molecules in 2016 and currently leads the Analytical group as an Associate Scientist. In this role, she provides analytical support to enable all aspects of DiCE Molecules platform and drug discovery efforts.
Prior to DiCE, Ms. Patel worked at Theravance Biopharma in Analytical Development group where she supported studies for Revefenacin (YUPELRI®) which is now in Phase III. In addition, she has provided analytical support for Ampreloxetine, TD-1473 (gut-selective pan-JAKi for Ulcerative colitis), PRIZM projects and Telavancin (VIBATIV®).
Ms. Patel holds B.S. in Pharmacy from Gujarat University and M.S. in Pharmaceutical Technology from L.J. Institute of Pharmacy, India.
This person is not in any offices
DiCE Molecules
DiCE Molecules designs and develops innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, they are developing oral alternatives to medicines currently limited to injectable forms.